These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36380976)

  • 21. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.
    Ao D; He X; Liu J; Xu L
    Signal Transduct Target Ther; 2023 Dec; 8(1):466. PubMed ID: 38129394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs for COVID-19: An Update.
    Ceramella J; Iacopetta D; Sinicropi MS; Andreu I; Mariconda A; Saturnino C; Giuzio F; Longo P; Aquaro S; Catalano A
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar T; Raut D; Bhatt LK
    Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
    Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
    Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.
    Bostanghadiri N; Ziaeefar P; Mofrad MG; Yousefzadeh P; Hashemi A; Darban-Sarokhalil D
    Biomed Res Int; 2023; 2023():1879554. PubMed ID: 37674935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological composition, efficacy and primary efficacy endpoint of SARS-CoV-2 vaccines: A special communication.
    Ishaque I; Muhib M; Khalid Jamil OB
    J Pak Med Assoc; 2022 Nov; 72(11):2264-2269. PubMed ID: 37013299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Pandemic of Coronavirus Disease 2019 (COVID-19).
    Rashid NN
    Curr Mol Med; 2022; 22(9):761-765. PubMed ID: 34789125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resolution of coronavirus disease 2019 (COVID-19).
    Habas K; Nganwuchu C; Shahzad F; Gopalan R; Haque M; Rahman S; Majumder AA; Nasim T
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1201-1211. PubMed ID: 32749914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development.
    Mehmood I; Ijaz M; Ahmad S; Ahmed T; Bari A; Abro A; Allemailem KS; Almatroudi A; Tahir Ul Qamar M
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.
    Zhou H; Ni WJ; Huang W; Wang Z; Cai M; Sun YC
    Front Immunol; 2022; 13():834942. PubMed ID: 35450063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coronavirus disease 2019 (COVID-19) vaccines: A concise review.
    Samaranayake LP; Seneviratne CJ; Fakhruddin KS
    Oral Dis; 2022 Nov; 28 Suppl 2():2326-2336. PubMed ID: 33991381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innovation-driven trend shaping COVID-19 vaccine development in China.
    Zhang Y; Zhao Y; Liang H; Xu Y; Zhou C; Yao Y; Wang H; Yang X
    Front Med; 2023 Dec; 17(6):1096-1116. PubMed ID: 38102402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review.
    Goyal M; Tewatia N; Vashisht H; Jain R; Kumar S
    J Infect Public Health; 2021 Jul; 14(7):910-921. PubMed ID: 34119845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
    Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging nanotechnology role in the development of innovative solutions against COVID-19 pandemic.
    Bhutta ZA; Kanwal A; Ali M; Kulyar MF; Yao W; Shoaib M; Ashar A; Mahfooz A; Ijaz M; Ijaz N; Asif M; Nawaz S; Mahfooz MR; Kanwal T
    Nanotechnology; 2021 Sep; 32(48):. PubMed ID: 34320471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms.
    Aileni M; Rohela GK; Jogam P; Soujanya S; Zhang B
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic.
    Kumar R; Harilal S; Al-Sehemi AG; Mathew GE; Carradori S; Mathew B
    Curr Med Chem; 2021; 28(15):2852-2886. PubMed ID: 32614740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.